FDA approves Novavax Covid vaccine after delay

The Food and Drug Administration (FDA) has finally granted approval for Novavax’s Covid-19 vaccine, but with certain restrictions that set it apart from its competitors in the U.S. market. The long-awaited license specifies that the vaccine can only be used for individuals aged 65 and older, as well as those aged 12 to 64 who have underlying medical conditions that increase their risk of severe illness if they were to contract Covid-19. This marks a significant milestone for Novavax, as the vaccine had previously been available under an emergency use authorization.

The FDA’s decision came after missing an April 1 deadline to rule on Novavax’s application. Reports surfaced that political appointees in Commissioner Marty Makary’s office overrode recommendations from career staff who had advised issuing the license. This move by the FDA has raised concerns and speculation in the industry, leading to a 21% decrease in Novavax’s stock price since the beginning of the year.

The approval of Novavax’s Covid-19 vaccine comes at a crucial time as the world continues to battle the ongoing pandemic. With restrictions in place, it is important for healthcare providers and individuals to adhere to the guidelines set forth by the FDA to ensure the safe and effective use of the vaccine.

For more in-depth analysis and exclusive content on this topic, subscribers can access additional information through STAT+. Subscribing to STAT+ offers access to newsletters, premium events, news alerts, and more. To unlock the full article and stay informed on the latest developments in the field of infectious diseases, consider subscribing to STAT+ today.